Structure-Based Design of erbB-2 Selective Small Molecule Kinase Inhibitors
Abstract
Our studies in the first two years have led to the identification of a number of promising "lead" compounds. Among these initial lead compounds, B-17 has excellent activity in inhibition of erbB-2 auto-phosphorylation and inhibition of cell proliferation using MDA-453 human breast cancer cells with erbB-2 overexpression. Furthermore, this compound appears to also be quite selective of breast cancer cells and model cells with EGFR overexpression but not erbB-2 overexpression (see below). Accordingly, B-17 represents a quite promising lead compound for further modifications.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2003
- Accession Number
- ADA419538
Entities
People
- Shaomeng Wang
Organizations
- University of Michigan